Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

References

  1. ACZ885 G2305 SJIA presentation (both G2305 and G2301) Brunner H, Ruperto N, Horneff G, et al. Efficacy and safety of canakinumab, a fully human anti-interleukin-1beta antibody, in active systemic juvenile idiopathic arthritis: Results from two Phase III studies. Presented on 9 November: The 2011 ACR Annual Scientific Meeting; November 5-9, 2011, Chicago, US. 2011.
  2. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006; 2(1):28-34
  3. Bailey KM, McDonagh JE, Prieur AM. Systemic juvenile idiopathic arthritis presenting in a young child with long term disability as an adolescent. Ann Rheum Dis 2004; 63(12):1544-8.
  4. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011; 7(7):416-26.
  5. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008; 4(1):34-42.
  6. Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford) 2005; 44(11):1350-3.
  7. Novartis data on file. Abrams K, Dimitrov-Kuhl M, Doerr T et al.  Clinical Study Protocol (CACZ885G2301): beta-SPECIFIC 2: Study of Pediatric EffiCacy wIth FIrst-line use of Canakinumab [A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations].  23 May 2011.

Novartis Media Relations 


'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Vala Sciences was recently awarded ... Agency (EPA). This new contract was awarded for ... tests designed to assess the effect of chemical ... connections between neurons (synapses), which are critical for ... by environmental pollutants likely contributes to a variety ...
(Date:7/29/2014)... MA (PRWEB) July 30, 2014 ... (UC) and collaboration company, is proud to announce ... account management positions in their Boston, Charleston and ... response to the increased demand for hosted solutions, ... operational efficiency and reduce cost. , SoundConnect was ...
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... that provides innovative genetic analysis solutions, and Mayo ... laboratory services in the United States ... testing patents and applications. "We have great ... patient care, and we welcome the opportunity to partner ...
(Date:7/29/2014)... of researchers has created a new way of ... These surfaces, made by self-assembly of carbon nanotubes, ... including controllable mechanical stiffness and strength, or the ... , "We have demonstrated that mechanical forces can ... three-dimensional microstructures, and that we can independently control ...
Breaking Biology Technology:U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4A new way to make microstructured surfaces 2
... small-molecule ... -, - Lead compound AEG40826 works synergistically with HGS TRAIL receptor ... drugs -, - IAP inhibitors also show promise alone and in ... cancer agents across broad range of cancers -, ROCKVILLE, Md. and MONTREAL, ...
... Inc. (OTC Bulletin Board: NWBO; AIM: NWBS ... Lonza Group AG has,withdrawn all claims of ... NWBT DCVax(R) products other than DCVax(R)-Prostate.,Lonza had ... infringed,certain gene expression technology patents held by ...
... Helix BioPharma Corp.,(TSX, FSE: "HBP") today announced ... for gross proceeds of CDN$16,867,200., About ... is a biopharmaceutical company specializing in,the field ... developing innovative,products for the prevention and treatment ...
Cached Biology Technology:Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 2Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 3Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 4Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 5Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 6Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 2Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 3Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 4Helix BioPharma closes $16.9 million private placement of common shares 2
(Date:7/30/2014)... been awarded the Scientific Committee on Antarctic Research,s ... , SCAR, an inter-disciplinary international science body, initiates, ... in the Antarctic region, and on the role ... The organisation also provides scientific advice about Antarctica ... the region. , The medal is open internationally ...
(Date:7/30/2014)... the roughly 3,000 pieces is still in its infant ... will be of major significance. "Amazingly often, we are ... Fushun amber that we found in Baltic amber," explained ... Baltic amber comes from the Baltic Sea region, which ... finds are, e.g., the coastal regions of Mecklenburg, Poland ...
(Date:7/29/2014)... BELLINGHAM, Washington, USA The advanced optical methods and ... are driving a revolution in the neurosciences were the ... published by SPIE, the international society for optics and ... of the BRAIN Initiative in the United States, and ... vision for and provide examples of the impact that ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3
... science prize was today awarded to a researcher who is looking ... someone in a noisy place, such as a party or bar, ... these situations. , Not being able to hear a person's voice ... most common problems for Britain's nine million people with a hearing ...
... Houston, Texas have found two bacterial muscle infections common ... the emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), according ... of Clinical Infectious Diseases, now available online. , Staphylococcus ... the skin or in the nose of a quarter ...
... two inexpensive technologies that may be able to prevent ... E. coli in contaminated spinach. , Together, these technologies ... first method uses a laser to detect and identify ... faster and one-tenth as expensive as current technology. ...
Cached Biology News:Train your brain to hear your friends at a party 2Train your brain to hear your friends at a party 3Train your brain to hear your friends at a party 4Study shows antibiotic-resistant bacteria responsible for increase in muscle infections 2Researchers develop technologies to devour food pathogens 2Researchers develop technologies to devour food pathogens 3
... Maxi Kit provides a fast and simple ... Triton X-100 and other detergents from ... using Norgens patented protein resin as an ... processing 0.25 - 8 mg of either ...
Values of steady state parameters for enzyme activities are determined....
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... Nucleic acid hybridization Preparation Reconstitution: ... BSA, 50 mg ficoll and ... 5 ml of water yields ... molecular biology Density: 1.00 g/mL ...
Biology Products: